Tag:

Galapagos

Latest Headlines

Latest Headlines

GlaxoSmithKline and Galapagos succeed in psoriasis after two setbacks

Galapagos and partner GlaxoSmithKline say their anti-inflammation candidate hit its mark in a mid-stage trial on psoriasis, a stroke of good news for a drug beset by developmental slipups.

Galapagos ships out its CRO biz for $179M to focus on R&D

Belgian biotech Galapagos is getting out of the CRO business, selling off its two contract units to preclinical giant Charles River Laboratories for $179 million and planning to put the proceeds into its pipeline.

Charles River snaps up Galapagos' CRO biz for $179M

Charles River Laboratories is looking to pad its preclinical prowess, inking a $179 million deal with drugmaker Galapagos for two CRO subsidiaries and a chance to expand its in vitro biology expertise.

GlaxoSmithKline hits the brakes on an anti-inflammatory drug from Galapagos

Galapagos NV's collaboration with GlaxoSmithKline has hit a roadblock. Late last week the Belgian biotech reported that its Big Pharma partner had hit the brakes on a Phase II study of GSK2586184 for lupus after a first look at the data failed to demonstrate a positive effect.

Galapagos reaps $46M payday as GSK preps PhII study

Belgium's Galapagos NV says that GlaxoSmithKline is prepping a Phase II study of GSK2586184 (formerly GLPG0778)--its JAK1 inhibitor--for ulcerative colitis.

AbbVie continues deal spree with $405M CF tie-up with Galapagos

A day after AbbVie unveiled an $840 million tie-up to develop a new anti-inflammatory therapy, the pharma company is continuing its deal spree today with a $405 million discovery pact on cystic fibrosis with Belgium's Galapagos.

AbbVie, Galapagos extend JAK1 pact into Crohn's disease with $50M carrot

The North Chicago, IL-based drug giant and Belgium's Galapagos have agreed to expand their collaboration on an oral JAK1 inhibitor to include Crohn's disease.

Roche dumps fibrosis alliance with Belgian biotech

Swiss drug giant Roche has exited an alliance with Belgium-based biotech Galapagos focused on fibrosis discovery, leaving Galapagos hunting for another partner to hunt for compounds against fibrotic diseases.

Abbott hits the sweet spot, pays $110M cash for PhIIb drug

The cash deal delivers AP214, in development to prevent acute kidney injury associated with major cardiac surgery.

J&J unit to pay $8.7M to Galapagos for drug candidate

Belgian biotech Galapagos has made progress in its alliance with the Janssen Pharmaceutica unit of healthcare giant Johnson & Johnson, revealing today that it has identified the first preclinical candidate in the collaboration.